BRAF and neoplasm: C1 appeared to be more invasive, with a higher proportion of patients with advanced T and N category, aggressive histological variants and extrathyroidal extension (ETE), and molecular changes mainly involving BRAF and other gene mutations, resulting in a worse prognosis (more RAI-refractory and new tumor events).